全文获取类型
收费全文 | 36507篇 |
免费 | 3504篇 |
国内免费 | 81篇 |
专业分类
耳鼻咽喉 | 298篇 |
儿科学 | 972篇 |
妇产科学 | 783篇 |
基础医学 | 4869篇 |
口腔科学 | 823篇 |
临床医学 | 4486篇 |
内科学 | 7371篇 |
皮肤病学 | 511篇 |
神经病学 | 3619篇 |
特种医学 | 1193篇 |
外国民族医学 | 1篇 |
外科学 | 5203篇 |
综合类 | 772篇 |
现状与发展 | 1篇 |
一般理论 | 24篇 |
预防医学 | 3524篇 |
眼科学 | 671篇 |
药学 | 3025篇 |
1篇 | |
中国医学 | 76篇 |
肿瘤学 | 1869篇 |
出版年
2021年 | 583篇 |
2020年 | 332篇 |
2019年 | 553篇 |
2018年 | 677篇 |
2017年 | 520篇 |
2016年 | 512篇 |
2015年 | 588篇 |
2014年 | 893篇 |
2013年 | 1231篇 |
2012年 | 1855篇 |
2011年 | 2049篇 |
2010年 | 1080篇 |
2009年 | 970篇 |
2008年 | 1661篇 |
2007年 | 1956篇 |
2006年 | 1727篇 |
2005年 | 1856篇 |
2004年 | 1613篇 |
2003年 | 1665篇 |
2002年 | 1545篇 |
2001年 | 921篇 |
2000年 | 954篇 |
1999年 | 845篇 |
1998年 | 440篇 |
1997年 | 352篇 |
1996年 | 336篇 |
1995年 | 356篇 |
1994年 | 319篇 |
1993年 | 298篇 |
1992年 | 670篇 |
1991年 | 611篇 |
1990年 | 597篇 |
1989年 | 583篇 |
1988年 | 539篇 |
1987年 | 545篇 |
1986年 | 474篇 |
1985年 | 577篇 |
1984年 | 491篇 |
1983年 | 380篇 |
1982年 | 356篇 |
1981年 | 314篇 |
1980年 | 304篇 |
1979年 | 421篇 |
1978年 | 356篇 |
1977年 | 270篇 |
1976年 | 297篇 |
1975年 | 242篇 |
1974年 | 318篇 |
1973年 | 314篇 |
1972年 | 277篇 |
排序方式: 共有10000条查询结果,搜索用时 906 毫秒
1.
2.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
3.
4.
5.
6.
Richard A. Lewis 《Journal of cataract and refractive surgery》2019,45(7):1051-1052
7.
8.
9.
Marleah Dean 《Health communication》2016,31(6):752-761
On May 14, 2013, Angelina Jolie disclosed she carries BRCA1, which means she has an 87% risk of developing breast cancer during her lifetime. Jolie decided to undergo a preventative bilateral mastectomy (PBM), reducing her risk to 5%. The purpose of this study was to analyze the type of information individuals are exposed to when using the Internet to search health information regarding Jolie’s decision. Qualitative content analysis revealed four main themes—information about genetics, information about a PBM, information about health care, and information about Jolie’s gender identity. Broadly, the identified websites mention Jolie’s high risk for developing cancer due to the genetic mutation BRCA1, describe a PBM occasionally noting reasons why she had this surgery and providing alternatives to the surgery, discuss issues related to health care services, costs, and insurances about Jolie’s health decision, and portray Jolie as a sexual icon, a partner to Brad Pitt, a mother of six children, and an inspirational humanitarian. The websites also depict Jolie’s health decision in positive, negative, and/or both ways. Discussion centers on how this actress’ health decision impacts the public. 相似文献
10.